<DOC>
	<DOC>NCT02106351</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of multiple doses of Dysport used in the treatment of upper limb spasticity (altered skeletal muscle performance) in children with cerebral palsy (CP).</brief_summary>
	<brief_title>Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children</brief_title>
	<detailed_description />
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Upper limb spasticity due to cerebral palsy Body weight 10 kg or over MAS score of 2 or more in affected elbow or wrist flexors Fixed myocontracture Previous phenol or alcohol injection within 1 year Severe athetoid or dystonic movements Previous or planned surgery for spasticity in elbow or wrist flexors Neuromuscular disorders Previous Rhizotomy within 6 months Intrathecal baclofen within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>